United States - English - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

rebel distributors corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is the nonproprietary name for the n-acetyl derivative of the naturally occurring amino acid, l-cysteine. chemically, it is n-acetyl-l-cysteine. the compound is a white crystalline powder which melts in the range of 104° to 110°c and has a very slight odor. the structural formula of acetylcysteine is: c5 h9 no3 s                                                                                                      m.w.=163.19 acetylcysteine solution, usp is supplied as a sterile unpreserved solution (not for injection) in vials containing a 10% (100 mg/ml) or 20% (200 mg/ml) solution of acetylcysteine as the sodium salt. the inactive ingredients are edetate disodium, sodium hydroxide and sterile water for injection, usp. the ph of the solution ranges from 6.0 to 7.5. it is administered by inhalation or direct instillation for mucolysis, or orally for acetaminophen overdosage.

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion. there are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

United States - English - NLM (National Library of Medicine)

american regent, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as po

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine solution, usp is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine solution, usp administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate trea

United States - English - NLM (National Library of Medicine)

hospira, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease     (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease     (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as

United States - English - NLM (National Library of Medicine)

arbor pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes . listeriosis caused by listeria monocytogenes . pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible ind

United States - English - NLM (National Library of Medicine)

versapharm incorporated - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 ml - erythromycin pledgets usp, 2% are indicated for the topical treatment of acne vulgaris. erythromycin pledgets usp, 2% are contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 ml - erythromycin topical solution is indicated for the topical treatment of acne vulgaris. erythromycin topical solution is contraindicated in those individuals who have shown hypersensitivity to any of its components.